Shs · CUSIP 869367201 · who reports it, how much, and how much it matters to them
17 of the 720 hedge fund managers we track reported shares of Sutro Biopharma, Inc. (Nasdaq: STRO) on Form 13F for 30 June 2026. Between them they reported USD 172m. The largest position belongs to Perceptive Advisors, at USD 43m. The manager with the most riding on it is Acuta Capital Partners, where it is 6.3% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Perceptive Advisors6 funds on PPLI.com | USD 43m | 0.7% |
| 2 | Kynam Capital Management1 fund on PPLI.com | USD 29m | 1.6% |
| 3 | Orbimed Advisors1 fund on PPLI.com | USD 25m | 0.5% |
| 4 | Balyasny Asset Management25 funds on PPLI.com | USD 24m | 0.0% |
| 5 | Millennium Management6 funds on PPLI.com | USD 12m | 0.0% |
| 6 | Acuta Capital Partners2 funds on PPLI.com | USD 9m | 6.3% |
| 7 | POINT72 Asset Management17 funds on PPLI.com | USD 7.9m | 0.0% |
| 8 | Two Sigma Investments35 funds on PPLI.com | USD 6.7m | 0.0% |
| 9 | Marshall Wace LLP84 funds on PPLI.com | USD 5.8m | 0.0% |
| 10 | Citadel Advisors32 funds on PPLI.com | USD 3.4m | 0.0% |
| 11 | Renaissance Technologies13 funds on PPLI.com | USD 2.9m | 0.0% |
| 12 | Squarepoint Ops7 funds on PPLI.com | USD 1.8m | 0.0% |
| 13 | D. E. Shaw & Co.15 funds on PPLI.com | USD 1m | 0.0% |
| 14 | Walleye Capital8 funds on PPLI.com | USD 309,000 | 0.0% |
| 15 | Lighthouse Investment Partners190 funds on PPLI.com | USD 278,000 | 0.0% |
| 16 | Persistent Asset Partners10 funds on PPLI.com | USD 218,000 | 0.1% |
| 17 | Verdad Advisers6 funds on PPLI.com | USD 212,000 | 0.2% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Acuta Capital Partners | USD 9m | 6.3% |
| 2 | Kynam Capital Management | USD 29m | 1.6% |
| 3 | Perceptive Advisors | USD 43m | 0.7% |
| 4 | Orbimed Advisors | USD 25m | 0.5% |
| 5 | Verdad Advisers | USD 212,000 | 0.2% |
| 6 | Persistent Asset Partners | USD 218,000 | 0.1% |
| 7 | Balyasny Asset Management | USD 24m | 0.0% |
| 8 | POINT72 Asset Management | USD 7.9m | 0.0% |
| 9 | Lighthouse Investment Partners | USD 278,000 | 0.0% |
| 10 | Two Sigma Investments | USD 6.7m | 0.0% |
Sutro Biopharma, Inc. trades under the symbol STRO on the Nasdaq. Its CUSIP, the code used on Form 13F, is 869367201.
17 of the 720 hedge fund managers PPLI.com tracks reported Sutro Biopharma, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Perceptive Advisors (USD 43m), Kynam Capital Management (USD 29m), Orbimed Advisors (USD 25m), Balyasny Asset Management (USD 24m) and Millennium Management (USD 12m).
17 managers in our coverage reported it, and between them they run 458 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Acuta Capital Partners, where the position was 6.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Sutro Biopharma, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.